HANXBIO-B repurchases 20,000 H shares at HK$30.13 average, boosting treasury stock to 106,100 shares

Bulletin Express04-10

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) reported to the Hong Kong Stock Exchange that it bought back 20,000 H shares on 10 April 2026. The repurchase represents 0.015% of the company’s outstanding shares (excluding treasury stock).

The shares were acquired on-market at a volume-weighted average price of HK$30.1278, within a trading range of HK$29.50–30.435238. Cash consideration for the transaction totaled HK$602,556. All 20,000 shares have been retained as treasury stock; no cancellations were recorded.

Following the buyback, issued shares outstanding (excluding treasury stock) declined from 136.13 million to 136.11 million. Treasury shares increased from 86,100 to 106,100, while total issued shares remained unchanged at 136.22 million.

The transaction forms part of the repurchase mandate approved on 12 February 2026, which authorizes HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 106,100 shares, equating to 0.0779% of the share count on the mandate date. In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100584645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-10 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100584645","market":"us","top_or_hot":-1,"title":"HANXBIO-B repurchases 20,000 H shares at HK$30.13 average, boosting treasury stock to 106,100 shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) reported to the Hong Kong Stock Exchange that it bought back 20,000 H shares on 10 April 2026. The repurchase represents 0.015% of the company’s outstanding shares (excluding treasury stock).</p>\n<p>The shares were acquired on-market at a volume-weighted average price of HK$30.1278, within a trading range of HK$29.50–30.435238. Cash consideration for the transaction totaled HK$602,556. All 20,000 shares have been retained as treasury stock; no cancellations were recorded.</p>\n<p>Following the buyback, issued shares outstanding (excluding treasury stock) declined from 136.13 million to 136.11 million. Treasury shares increased from 86,100 to 106,100, while total issued shares remained unchanged at 136.22 million.</p>\n<p>The transaction forms part of the repurchase mandate approved on 12 February 2026, which authorizes HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 106,100 shares, equating to 0.0779% of the share count on the mandate date. In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B repurchases 20,000 H shares at HK$30.13 average, boosting treasury stock to 106,100 shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B repurchases 20,000 H shares at HK$30.13 average, boosting treasury stock to 106,100 shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-10 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) reported to the Hong Kong Stock Exchange that it bought back 20,000 H shares on 10 April 2026. The repurchase represents 0.015% of the company’s outstanding shares (excluding treasury stock).</p>\n<p>The shares were acquired on-market at a volume-weighted average price of HK$30.1278, within a trading range of HK$29.50–30.435238. Cash consideration for the transaction totaled HK$602,556. All 20,000 shares have been retained as treasury stock; no cancellations were recorded.</p>\n<p>Following the buyback, issued shares outstanding (excluding treasury stock) declined from 136.13 million to 136.11 million. Treasury shares increased from 86,100 to 106,100, while total issued shares remained unchanged at 136.22 million.</p>\n<p>The transaction forms part of the repurchase mandate approved on 12 February 2026, which authorizes HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 106,100 shares, equating to 0.0779% of the share count on the mandate date. In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1100584645","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100584645","pubTimestamp":1775821464,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) reported to the Hong Kong Stock Exchange that it bought back 20,000 H shares on 10 April 2026. The repurchase represents 0.015% of the company’s...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"HANXBIO-B以平均30.13港元回购20,000股H股，库存股增至106,100股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) reported to the Hong Kong Stock Exchange that it bought back 20,000 H shares on 10 April 2026. The repurchase represents 0.015% of the company’s outstanding shares (excluding treasury stock).\nThe shares were acquired on-market at a volume-weighted average price of HK$30.1278, within a trading range of HK$29.50–30.435238. Cash consideration for the transaction totaled HK$602,556. All 20,000 shares have been retained as treasury stock; no cancellations were recorded.\nFollowing the buyback, issued shares outstanding (excluding treasury stock) declined from 136.13 million to 136.11 million. Treasury shares increased from 86,100 to 106,100, while total issued shares remained unchanged at 136.22 million.\nThe transaction forms part of the repurchase mandate approved on 12 February 2026, which authorizes HANXBIO-B to buy back up to 13.62 million shares. Cumulative repurchases under this mandate now stand at 106,100 shares, equating to 0.0779% of the share count on the mandate date. In accordance with Hong Kong Listing Rules, the company is subject to a moratorium on new share issues or treasury-share sales until 10 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100584645","isCrawlerRequest":true}